{{Rsnum
|rsid=1449683
|Gene=FGF2
|Chromosome=4
|position=122826931
|Orientation=plus
|GMAF=0.1607
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FGF2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 76.8 | 21.4 | 1.8
| HCB | 82.1 | 17.2 | 0.7
| JPT | 77.0 | 21.2 | 1.8
| YRI | 51.4 | 39.0 | 9.6
| ASW | 40.4 | 49.1 | 10.5
| CHB | 82.1 | 17.2 | 0.7
| CHD | 71.6 | 25.7 | 2.8
| GIH | 83.2 | 16.8 | 0.0
| LWK | 53.7 | 40.7 | 5.6
| MEX | 53.4 | 39.7 | 6.9
| MKK | 0.0 | 0.0 | 0.0
| TSI | 91.0 | 7.0 | 2.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=19586755
|Title=Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects
}}

{{PMID Auto
|PMID=22315135
|Title=The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}